

Cervical cancer



2nd most common cause of **women cancer** in developing countries
More than **90%** cases infected by **Human Papilloma Virus (HPV)**



Inequality in incidence in Europe

How to prevent HPV related disease ?



Screening



Preventive vaccines in healthy women



Chemotherapy



Surgery



Radiotherapy

Novel treatment strategies

2 precision medicine approaches



Target the tumor molecular abnormalities

Extensive tumor characterization using high throughput techniques



DNA sequencing



Protein analyses



Blood markers



Tumor micro environment


1st Biobanking study in Europe

Bioinformatics and data integration

Clinical Data
France



Protein analyses
France



Tumor micro environment
Netherlands



Blood markers
Netherlands



DNA sequencing
Hungary

Clinical results



Target the tumor molecular abnormalities

Identification of patient's groups



Target the virus with DNA vaccines

First clinical trials completed and new DNA vaccine

Preclinical studies based on molecular profile

New drugs and drug combination for precision medicine

Cell lines
Mouse models



Treatment 1



Treatment 2



Treatment 3



Treatment 4



Treatment 5

Preclinical results



Importance of combination strategies to control cancer progression



Patent submitted

RAIDS Perspectives

First biobanking study in Europe



Future design of precision medicine clinical trial

Early stage treatments in future precision medicine clinical trials RAIDS 2 CURE

Key figures



400 patients included in BioRAIDS study



12 DNA vaccines



54 months duration



18 partners



6M€ Grant

Cervical cancer



2nd most common cause of women cancer in developing countries
More than **90%** cases infected by Human Papilloma Virus (HPV)



Inequality in incidence in Europe

How to prevent HPV related disease ?



Screening



Preventive vaccines in healthy women



Chemotherapy



Surgery



Radiotherapy

How to treat cervical cancer ?

Novel treatment strategies

2 precision medicine approaches



Target the tumor molecular abnormalities
Extensive tumor characterization using high throughput techniques



DNA sequencing



Protein analyses



Target the virus with DNA vaccines
Strengthen immune system
Fight cancer induced by HPV virus



Blood markers



Tumor micro environment

1st Biobanking study in Europe


Bioinformatics and data integration

Clinical results

Clinical Data
France



Protein analyses
France



Tumor micro environment
Netherlands

Blood markers
Netherlands

DNA sequencing
Hungary



Target the tumor molecular abnormalities

Identification of patient's groups



Target the virus with DNA vaccines

First clinical trials completed and new DNA vaccine

Preclinical studies based on molecular profile

New drugs and drug combination for precision medicine

Preclinical results

Cell lines
Mouse models



Importance of combination strategies to control cancer progression



Patent submitted

RAIDs Perspectives

First biobanking study in Europe

Key figures



Future design of precision medicine clinical trial
Early stage treatments in future precision medicine clinical trials RAIDs 2 CURE



400 patients included in BioRAIDs study



12 DNA vaccines



54 months duration



18 partners



6M€ Grant



Institut Curie

Dr Maud Kamal - maud.kamal@curie.fr
Dr Suzy Scholl - suzy.scholl@gmail.com

